Business Context and Reporting Period
Company: Invizyne Technologies Inc. (Note: Input metadata referenced "Exozymes Inc.", but the filing text identifies the registrant as Invizyne Technologies Inc., trading symbol IZTC).
Reporting Period: Quarterly Report (Form 10-Q) for the period ended September 30, 2024.
Business Overview: Invizyne is a pre-revenue, development-stage biotechnology company focused on a synthetic biology platform ("SimplePath") for cell-free, multi-step enzyme-based biomanufacturing. The company is a subsidiary of MDB Capital Holdings, LLC (approx. 48% ownership as of the report date). The filing includes a "Going Concern" warning, noting that without additional financial support, the company may not meet obligations for the next year.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Sept 30, 2024 Balance Sheet |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,656,373) | $(4,025,361) | N/A |
| Operating Costs | $1,611,726 | $3,948,789 | N/A |
| Cash and Equivalents | N/A | N/A | $233,935 |
| Total Assets | N/A | N/A | $3,560,365 |
| Total Liabilities | N/A | N/A | $7,161,683 |
| Working Capital | N/A | N/A | $(4,379,709) |
| Related Party Debt | N/A | N/A | $3,414,093 (Note) + $255,840 (Due to Affiliates) |
Cash Flow (Nine Months 2024): Net cash used in operating activities was $(2,798,123). Net cash used in investing activities was $(148,809). Net cash provided by financing activities was $3,114,334, primarily from related party loans.
Material Changes vs. Prior Period
- Revenue: The company reported $0 operating income for the three and nine months ended September 30, 2024, compared to $0 and $70,769 respectively in 2023.
- Net Loss: Net loss increased significantly to $(4.03) million for the nine months ended September 30, 2024, compared to $(0.94) million in the same period in 2023. This represents a 328% increase.
- Operating Expenses: Total operating costs rose 348% year-over-year for the nine-month period. General and administrative costs increased 233% (driven by compensation and professional fees for IPO preparation), and R&D costs (net of grants) increased 1,746%.
- Liabilities: Total liabilities increased 82% to $7.16 million, largely due to the recognition of a $3.41 million related party note and increased accounts payable.
- Grants: Grants receivable decreased by $328,356 to $553,963 due to the completion of certain grants and drawdowns.
Outlook, Risks, and Subsequent Events
Subsequent Events (Post-Sept 30, 2024):
- IPO Completion: On November 11, 2024, the company signed an underwriting agreement for an IPO, selling 1,875,000 shares for gross proceeds of $15,000,000 (net proceeds approx. $14.32 million). The IPO closed on November 13, 2024.
- Debt Repayment: Proceeds from the IPO are designated to repay approximately $4.39 million in intercompany loans to MDB Capital Holdings, LLC.
- Stock Split: A 2-for-1 stock split was approved on October 3, 2024, with retroactive adjustments to share counts and prices in the filing.
- New Grant: In October 2024, the company received a $1,000,000 cost-share grant from the Department of Defense (DOD) BioMADE initiative.
Risks and Contingencies:
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern without the IPO proceeds or additional financing.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, concluding that disclosure controls were not effective as of September 30, 2024.
- Technology Risk: As a pre-revenue company, there is significant uncertainty regarding the commercial viability and regulatory approval of its synthetic biology platform.
Investor Verification Checklist
- IPO Proceeds Utilization: Verify the actual closing of the IPO and the immediate repayment of the $4.39 million related party debt to MDB Capital Holdings.
- Going Concern Status: Confirm that the post-IPO working capital position (estimated at ~$9.9 million) is sufficient to fund operations for the next 12 months without further dilution.
- Grant Sustainability: Assess the timeline for the new DOD grant and the status of existing NIH and Department of Energy grants to ensure continued R&D funding offsets.
- Internal Controls Remediation: Review future filings for progress on remediation of the material weaknesses in internal controls identified in this report.
- Related Party Transactions: Monitor the terms of the remaining related party balances and ensure no new undisclosed advances are made post-IPO.